BioSpace News Archive

Revance Therapeutics, Inc. announced today it will present two video abstracts featuring DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection at the American Society for Dermatologic Surgery (ASDS) Annual Meeting taking place in Aurora, CO, from October 6-10, 2022.

Vektor Medical, the developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, announced study results that demonstrate a significant reduction in total procedural duration, fluoroscopy use, and cost after implementation of vMap®.

Enable Biosciences, a leading diabetes and COVID diagnostics firm and CLIA- and CAP- certified laboratory, announced that Carolyn Bertozzi , PhD, co-founder of Enable Biosciences, was awarded the 2022 Nobel Prize in Chemistry for “the development of click chemistry and bioorthogonal chemistry.”

Lineage Cell Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to grant a patent for the Company’s U.S. patent application No. 16/750,975, entitled “Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells.”

Immune-Onc Therapeutics, Inc. today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China.

Ray Therapeutics and Forge Biologics announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics gene therapy program, RTx-015, in clinical trials for patients with retinitis pigmentosa.

Tenax Therapeutics, Inc. announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the SPN-830 New Drug Application (NDA).

Rapid Micro Biosystems, Inc. today announced its newest product, RMBNucleus™ Mold Alarm, which is designed to rapidly detect environmental molds in the pharmaceutical manufacturing process.

Anixa Biosciences, Inc. today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022.